Tocilizumab study offers new hope for children with arthritis

A new study has confirmed significant improvements after treatment with tocilizumab amongst children with systemic juvenile idiopathic arthritis (sJIA), who do not tolerate or have an inadequate response to conventional therapies. Professor Shumpei Yokota presented the encouraging results of the first double-blind, placebo controlled trial for tocilizumab at the Annual European Congress of Rheumatology in Amsterdam today (Thursday 22 June).

Juvenile Idiopathic Arthritis (JIA) is a relatively rare disease, affecting 30 to 150 children per 100,000 per year in Europe.1 "Systemic JIA is a specific type of juvenile idiopathic arthritis and it is one of the most severe types as it affects the whole body and most of the joints. As well as swollen and painful joints, the child has rashes, high fever, is severely lacking in energy and is generally very unwell", said Professor Yokota.

Tocilizumab, previously known as MRA, is currently undergoing phase III trials for moderate to severe adult onset rheumatoid arthritis (RA) as well as sJIA. Tocilizumab blocks the action of a protein, called interleukin 6 (IL-6), which provokes inflammation.

The study presented by Professor Yokota and the research team involved a total of 56 children, 35 of them were female, and the mean age was 8.3 years old. Disease activity was assessed in a number of ways such as number of active joints, number of joints with limitations of motion, physician's/parent's global assessment, two inflammatory disease parameters (ESR and CRP) and through a parental heath assessment questionnaire (CHAQ). 68% of the children had an improvement rate of 70%, while more than 85% had an improvement rate of 50%. Treatment was generally well tolerated, though two patients experienced serious adverse events; one anaphylactoid reaction and one gastrointestinal hemorrhage. Both patients returned to normal after discontinuation of tocilizumab.

"The goals of the treatment for children with arthritis are to relieve pain and inflammation, slow down or prevent the destruction of joints, as well as restore use and function of the joints to promote optimal growth, physical activity, and social and emotional development in the child. This study confirms that tocilizumab is one of the most promising therapies to treat children with sJIA who have not benefited from conventional therapies", said Professor Yokota.



1. Gare AB. Juvenile arthritis - who gets it, where and when? A review of current data on incidence and prevalence. Clin Exp Rheum 1999;17:367-74.

For further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress press office on:

Email: [email protected]

Jim Baxter - Onsite tel: +44 (0) 7900 605652
Jo Spadaccino - Onsite tel: +44 (0) 7773 271930
Mia Gannedahl - Office tel: +44 (0) 20 7331 2325

Abstract number: OP0021


  • The European League Against Rheumatism (EULAR) is the organization which represents the patient, health professional and scientific societies of rheumatology of all the European nations.
  • The aims of EULAR are to reduce the burden of rheumatic diseases on the individual and society and to improve the treatment, prevention and rehabilitation of musculoskeletal diseases. To this end, EULAR fosters excellence in education and research in the field of rheumatology. It promotes the translation of research advances into daily care and fights for the recognition of the needs of people with musculoskeletal diseases by the governing bodies in Europe.
  • Diseases of bones and joints, such as rheumatoid arthritis and osteoarthritis cause disability in 4 - 5 % of the adult population and are predicted to rise as people live longer.
  • As new treatments emerge and cellular mechanisms are discovered, the 7th Annual European Congress of Rheumatology in Amsterdam (EULAR 2006) brings together more than 10,000 experts - scientists, clinicians, healthcare workers, pharmaceutical companies and patients - to share their knowledge in a global endeavour to challenge the pain and disability caused by musculo-skeletal disorders.
  • To find out more information about the activities of EULAR, visit:

Last reviewed: By John M. Grohol, Psy.D. on 30 Apr 2016
    Published on All rights reserved.